Literature DB >> 31386933

Transdermal lipid vesicular delivery of iloperidone: Formulation, in vitro and in vivo evaluation.

Vaishali Y Londhe1, Bhavya Bhasin2.   

Abstract

The objective of present study was to develop and evaluate lipid vesicular transdermal system of iloperidone. Liposomes were prepared successfully using thin film hydration method. With aim of enhancing permeation, cholesterol from liposomes was replaced with transcutol to give PEVs. Liposomes and PEVs were evaluated for particle size, shape, entrapment efficiency, viscosity and release study. The vesicles were incorporated in 0.5% of Carbopol gel and evaluated. Particle size of liposomes and PEVs was found between 200-300 nm and entrapment efficiency was found 80-90%w/w. The transdermal gels were homogeneous, spreadable having acceptable pH and drug content between 90-100%.In ex vivo studies, both liposomes and PEVs showed relatively higher skin deposition and permeation of Iloperidone than the plain drug without vesicles. The in vivo pharmacokinetics studies showed relative bioavailability of the PEV loaded gel as 62% and 166% when compared to the oral drug and gel without vesicles respectively. Pharmacodynamic studies showed FRT and HRT delay responses of the transdermal gel systems were significant[p < 0.05] as compared to control at the end of 24 hs. Thus, it can be concluded that transdermal delivery system can be a promising approach for sustained delivery of Iloperidone.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Iloperidone; Liposomes; Paw test; Permeation enhancing vesicles (PEVs); Pharmacokinetics; Transdermal delivery

Mesh:

Substances:

Year:  2019        PMID: 31386933     DOI: 10.1016/j.colsurfb.2019.110409

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  1 in total

1.  A comparison of dissolving microneedles and transdermal film with solid microneedles for iloperidone in vivo: a proof of concept.

Authors:  Rupali S Bhadale; Vaishali Y Londhe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-10-22       Impact factor: 3.195

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.